Patients with insomnia and apnea saw a bigger blood-pressure drop from CPAP

Comorbid insomnia and obstructive sleep apnea — COMISA — is generally framed in the research literature as a higher-risk phenotype, associated with worse blood pressure control and, per other research published earlier this year, higher mortality than either condition alone. A study published this month in Chest complicates that framing in one specific respect: whether COMISA patients respond differently to CPAP treatment itself [s1].

The design

Researchers conducted a prospective cohort study of 71 adults with obstructive sleep apnea and elevated blood pressure, who underwent four weeks of auto-CPAP therapy [s1]. Participants were stratified into a COMISA group (n=22) and an OSA-alone group (n=49) based on DSM-5 insomnia criteria [s1]. The primary outcome was a clinically meaningful reduction in 24-hour systolic blood pressure — defined as a decrease of at least 5 mmHg [s1]. Secondary outcomes tracked absolute changes in 24-hour, daytime, and nocturnal systolic and diastolic blood pressure [s1].

What it found

After four weeks of CPAP, the COMISA group achieved a significantly greater reduction in 24-hour systolic blood pressure than the OSA-alone group: −6.0 ± 8.2 mmHg versus −0.3 ± 6.5 mmHg (p = 0.002) [s1], with consistent benefit patterns across daytime and nocturnal measurements too. Insomnia symptoms were independently associated with achieving the primary clinically-meaningful blood pressure reduction outcome, with an adjusted odds ratio of 5.62 (95% CI 1.50–21.15) [s1]. The secondary outcome associations (specific daytime and nocturnal systolic blood pressure changes) did not remain statistically significant after applying a Bonferroni correction — a standard statistical adjustment used to reduce the risk of false positives when testing multiple related outcomes at once [s1].

Why this cuts against how COMISA is usually discussed

Comorbid insomnia is typically framed, including in other research published this year, as compounding sleep apnea's risks — worse blood pressure control, higher mortality. This study's finding — that the COMISA group actually responded better to CPAP's blood-pressure-lowering effect than the apnea-alone group — doesn't contradict that broader risk framing so much as add a specific, more encouraging nuance to it: even if COMISA carries elevated baseline cardiovascular risk, this data suggests CPAP therapy may be a particularly effective lever for addressing at least one component of that risk (blood pressure) in exactly this higher-risk group, rather than being a less effective treatment for a population that already faces worse outcomes.

Why the Bonferroni-adjustment detail matters for how confidently to read this

The primary outcome (achieving a clinically meaningful 24-hour systolic blood pressure drop) held up as statistically significant with a fairly robust-looking odds ratio (5.62), but the secondary, more granular blood pressure measures lost statistical significance once adjusted for the number of comparisons tested [s1]. That's the kind of transparent reporting that should shape how much weight to put on each individual number: the headline primary finding is reasonably solid, but the more detailed breakdown by time-of-day blood pressure changes should be treated as suggestive rather than confirmed.

What this doesn't establish

Seventy-one participants split into a 22-person COMISA group and a 49-person OSA-alone group is a modest sample, particularly for the smaller subgroup, which limits how precisely the true effect size can be estimated and increases the chance that this specific finding, however statistically significant, doesn't fully replicate in a larger cohort. This is a single-cohort, non-randomized comparison (both groups received the same CPAP treatment; they weren't randomized to different treatments) — it demonstrates that COMISA patients showed a bigger response to CPAP than OSA-alone patients did, not that some other intervention specific to insomnia produced this effect. The study's four-week window is short, and doesn't address whether this enhanced CPAP response in COMISA patients persists over longer treatment durations.

What the authors suggest

The study's authors frame COMISA as "a clinical phenotype with an enhanced SBP-lowering response to CPAP" and argue that strategies to improve CPAP adherence specifically in COMISA patients are important, given both the elevated baseline risk this phenotype carries and its apparently strong treatment responsiveness [s1] — reasoning that ties directly back to the well-documented challenge that comorbid insomnia can itself make CPAP harder to tolerate and adhere to consistently.

What to watch

Whether this enhanced blood-pressure response in COMISA patients holds up in larger, longer-duration studies, and whether it translates into better long-term cardiovascular outcomes for this specific phenotype. This article is not medical advice.

Sources

1. Comorbid Insomnia is Associated with Enhanced Blood Pressure Reduction with CPAP Therapy in Patients with Obstructive Sleep Apnea: A Prospective Cohort Study — Chest, 31 July 2026